These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 11446525)
1. New directions in antiinfective therapy for community-acquired pneumonia in the emergency department. Moran GJ Pharmacotherapy; 2001 Jul; 21(7 Pt 2):95S-99S. PubMed ID: 11446525 [TBL] [Abstract][Full Text] [Related]
2. The use of fluoroquinolones as antiinfective transition-therapy agents in community-acquired pneumonia. Press RA Pharmacotherapy; 2001 Jul; 21(7 Pt 2):100S-104S. PubMed ID: 11446520 [TBL] [Abstract][Full Text] [Related]
3. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274 [TBL] [Abstract][Full Text] [Related]
4. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization. Corrêa JC; Badaró R; Bumroongkit C; Mera JR; Dolmann AL; Juárez Martínez LG; Mayrinck LR; Tamez R; Yang JY Clin Ther; 2003 May; 25(5):1453-68. PubMed ID: 12867221 [TBL] [Abstract][Full Text] [Related]
5. Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia. Clark LC; Davis CW Am J Health Syst Pharm; 2000 Nov; 57 Suppl 3():S10-3. PubMed ID: 11098314 [TBL] [Abstract][Full Text] [Related]
6. Community-acquired pneumonia in the elderly: a practical guide to treatment. Lieberman D; Lieberman D Drugs Aging; 2000 Aug; 17(2):93-105. PubMed ID: 10984198 [TBL] [Abstract][Full Text] [Related]
7. Diagnosis and management of community-acquired pneumonia in adults. Watkins RR; Lemonovich TL Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712 [TBL] [Abstract][Full Text] [Related]
8. Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients. Izadi M; Dadsetan B; Najafi Z; Jafari S; Mazaheri E; Dadras O; Heidari H; SeyedAlinaghi S; Voltarelli F Recent Pat Antiinfect Drug Discov; 2018; 13(3):228-239. PubMed ID: 30360748 [TBL] [Abstract][Full Text] [Related]
9. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study. Frei CR; Jaso TC; Mortensen EM; Restrepo MI; Raut MK; Oramasionwu CU; Ruiz AD; Makos BR; Ruiz JL; Attridge RT; Mody SH; Fisher A; Schein JR Curr Med Res Opin; 2009 Apr; 25(4):859-68. PubMed ID: 19231913 [TBL] [Abstract][Full Text] [Related]
11. Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward: results from the United States Community-Acquired Pneumonia Project. Frei CR; Koeller JM; Burgess DS; Talbert RL; Johnsrud MT Pharmacotherapy; 2003 Sep; 23(9):1167-74. PubMed ID: 14524648 [TBL] [Abstract][Full Text] [Related]
12. Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience. Milkovich G Pharmacotherapy; 2001 Jul; 21(7 Pt 2):83S-88S. PubMed ID: 11446523 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Dresser LD; Niederman MS; Paladino JA Chest; 2001 May; 119(5):1439-48. PubMed ID: 11348951 [TBL] [Abstract][Full Text] [Related]
14. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review. Oosterheert JJ; Bonten MJ; Hak E; Schneider MM; Hoepelman IM J Antimicrob Chemother; 2003 Oct; 52(4):555-63. PubMed ID: 12972448 [TBL] [Abstract][Full Text] [Related]
15. Antimicrobial therapy for community-acquired pneumonia in adults. da Cunha CA; Sader HS; Nicodemo AC; Braz J Infect Dis; 2002 Apr; 6(2):82-7. PubMed ID: 11980608 [TBL] [Abstract][Full Text] [Related]
16. Approaches to drug therapy, formulary, and pathway management in a large community hospital. Halley HJ Am J Health Syst Pharm; 2000 Nov; 57 Suppl 3():S17-21. PubMed ID: 11098316 [TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. File TM Clin Infect Dis; 2004 Sep; 39 Suppl 3():S159-64. PubMed ID: 15546111 [TBL] [Abstract][Full Text] [Related]
18. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study. Llop CJ; Tuttle E; Tillotson GS; LaPlante K; File TM Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542 [TBL] [Abstract][Full Text] [Related]
19. Community-Acquired Pneumonia in Adults: Diagnosis and Management. Kaysin A; Viera AJ Am Fam Physician; 2016 Nov; 94(9):698-706. PubMed ID: 27929242 [TBL] [Abstract][Full Text] [Related]
20. Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia. Gilbert K; Gleason PP; Singer DE; Marrie TJ; Coley CM; Obrosky DS; Lave JR; Kapoor WN; Fine MJ Am J Med; 1998 Jan; 104(1):17-27. PubMed ID: 9528715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]